Recent Analysts’ Ratings Updates for Regeneron Pharmaceuticals (REGN)

A number of firms have modified their ratings and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) recently:

• 2/16/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/9/2026 – Regeneron Pharmaceuticals had its price target raised by Guggenheim from $865.00 to $975.00. They now have a “buy” rating on the stock.
• 2/8/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/6/2026 – Regeneron Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 2/2/2026 – Regeneron Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $850.00 to $950.00. They now have an “overweight” rating on the stock.
• 2/2/2026 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up from $750.00.
• 2/2/2026 – Regeneron Pharmaceuticals had its price target raised by Morgan Stanley from $768.00 to $769.00. They now have an “equal weight” rating on the stock.
• 2/2/2026 – Regeneron Pharmaceuticals had its price target raised by Cantor Fitzgerald from $740.00 to $800.00. They now have an “overweight” rating on the stock.
• 2/2/2026 – Regeneron Pharmaceuticals had its price target raised by Wells Fargo & Company from $745.00 to $800.00. They now have an “equal weight” rating on the stock.
• 2/2/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $820.00 to $818.00. They now have a “buy” rating on the stock.
• 1/31/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/22/2026 – Regeneron Pharmaceuticals had its price target raised by Evercore Inc from $750.00 to $875.00. They now have an “outperform” rating on the stock.
• 1/10/2026 – Regeneron Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/8/2026 – Regeneron Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 1/8/2026 – Regeneron Pharmaceuticals had its price target raised by Truist Financial Corporation from $798.00 to $820.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Regeneron Pharmaceuticals was upgraded by Bank of America Corporation from “underperform” to “buy”. They now have a $860.00 price target on the stock, up from $627.00.
• 12/29/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.